primary peritoneal cancer
Showing 1 - 25 of 88
Ovarian Cancer, High Grade Serous Adenocarcinoma of Ovary, High Grade Endometrioid Ovarian Cancer Trial in Guangzhou (Fluzoparib
Not yet recruiting
- Ovarian Cancer
- +4 more
- Fluzoparib Capsules
- Bevacizumab
-
Guangzhou, Guangdong, ChinaSun Yat-sen University Cancer Cetntre
Sep 25, 2023
Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer Trial (Luveltamab tazevibulin, Pegfilgrastim)
Not yet recruiting
- Ovarian Cancer
- +4 more
- Luveltamab tazevibulin
- Pegfilgrastim
- (no location specified)
May 12, 2023
Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer Trial in Houston (Paclitaxel, Carboplatin, Bevacizumab)
Recruiting
- Ovarian Cancer
- +2 more
- Paclitaxel
- +3 more
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Feb 13, 2023
High Grade Serous Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer Trial in Cambridge (Upifitimab rilsodotin,
Recruiting
- High Grade Serous Ovarian Cancer
- +2 more
- Upifitimab rilsodotin
- Placebo
-
Phoenix, Arizona
- +40 more
Jan 25, 2023
Homologous Recombination Inquiry Through Ovarian Malignancy
Completed
- Ovarian Cancer
- +2 more
-
Niigata city, Niigata Prefecture, JapanNiigata University Graduate School of Medical and Dental Science
Jan 19, 2023
Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer Trial in New Haven, Baltimore (Ixabepilone,
Active, not recruiting
- Epithelial Ovarian Cancer
- +2 more
-
New Haven, Connecticut
- +1 more
Jan 11, 2023
Mucinous Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer Trial in Seoul (Bevacizumab + modified FOLFIRINOX)
Recruiting
- Mucinous Ovarian Cancer
- +2 more
- Bevacizumab + modified FOLFIRINOX
-
Seoul, Korea, Republic ofYonsei University Health System, Severance Hospital
Dec 25, 2022
Renal Cell Carcinoma (RCC), Urothelial Carcinoma, Primary Peritoneal Cancer Trial in Canada, United States (DSP-7888 Dosing
Completed
- Renal Cell Carcinoma (RCC)
- +5 more
- DSP-7888 Dosing Emulsion
- +2 more
-
Tucson, Arizona
- +18 more
Dec 6, 2022
Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer Trial in New York (NY-ESO-1 OLP4, NY-ESO-1 OLP4 +
Completed
- Epithelial Ovarian Cancer
- +2 more
- NY-ESO-1 OLP4
- +2 more
-
New York, New YorkMemorial Sloan-Kettering Cancer Center
Oct 3, 2022
High-Grade Ovarian Cancer Terms of Homologous Recombination
Not yet recruiting
- Ovarian Cancer
- +2 more
- Standard of care
- (no location specified)
Oct 7, 2022
Solid Tumor, Colorectal Cancer, Cholangiocarcinoma Trial in France, United States (TRK-950, Irinotecan, Leucovorin)
Recruiting
- Solid Tumor
- +11 more
- TRK-950
- +14 more
-
Scottsdale, Arizona
- +13 more
Oct 2, 2022
Rucaparib in Rucaparib Access Program in Spain - A GEICO Study
Completed
- Epithelial Ovarian Cancer
- +2 more
-
Almería, Andalucía, Spain
- +22 more
Sep 22, 2022
Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Cancer, Fallopian Tube Cancer Trial in Orlando, Albuquerque
Recruiting
- Platinum-resistant Ovarian Cancer
- +6 more
- olvimulogene nanivacirepvec
- +3 more
-
Orlando, FloridaAdventHealth Cancer Institute
Sep 1, 2022
Epithelial Ovarian, Fallopian Tube, Primary Peritoneal Cancer Trial in Houston (Paclitaxel/Bev (control), Paclitaxel/Bev + ZA
Recruiting
- Epithelial Ovarian
- +2 more
- Paclitaxel/Bev (control)
- Paclitaxel/Bev + ZA (experimental)
-
Houston, TexasM D Anderson Cancer Center
Aug 9, 2022
Platinum-resistant Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer Trial in Canada, United States (Nemvaleukin
Recruiting
- Platinum-resistant Ovarian Cancer
- +2 more
- Nemvaleukin and Pembrolizumab Combination
- +6 more
-
Ventura, California
- +7 more
Aug 5, 2022
Recurrent Ovarian Cancer, Recurrent Fallopian Tube Cancer, Primary Peritoneal Cancer Trial (Niraparib, Dostarlimab)
Not yet recruiting
- Recurrent Ovarian Cancer
- +2 more
- (no location specified)
Jul 26, 2022
High Grade Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer Trial (Mirvetuximab soravtansine, Carboplatin)
Not yet recruiting
- High Grade Ovarian Cancer
- +2 more
- Mirvetuximab soravtansine
- Carboplatin
- (no location specified)
Jul 11, 2022
Ovarian Cancer, Fallopian Tube, Primary Peritoneal Cancer Trial in Birmingham (mirvetuximab soravtansine (MIRV; IMGN853))
Recruiting
- Ovarian Cancer
- +2 more
- mirvetuximab soravtansine (MIRV; IMGN853)
-
Birmingham, AlabamaUniversity of Alabama at Birmingham Womens & Infants Center
Jun 30, 2022
Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer Trial in Toronto (Niraparib, Dostarlimab, Bevacizumab)
Not yet recruiting
- Ovarian Cancer
- +4 more
- Niraparib
- +3 more
-
Toronto, Ontario, CanadaPrincess Margaret Cancer Centre
May 2, 2022